A potential therapeutic target for FLT3-ITD AML: PIM1 kinase

Leukemia Research

Volumn 36, Issue 2, 2012, Pages 224-231

  Fathi, Amir T ^a   Arowojolu, Omotayo ^b   Swinnen, Ian ^b   Sato, Takashi ^b   Rajkhowa, Trivikram ^b   Small, Donald ^b   Marmsater, Fredrik ^c   Robinson, John E ^c   Gross, Stefan David ^c   Martinson, Matthew ^c   Allen, Shelley ^c   Kallan, Nicholas C ^c   Levis, Mark ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ARRAY BIOPHARMA INC   (United States)

Author keywords

Acute myeloid leukemia; FLT3; Internal tandem duplication; PIM1 kinase; Targeted therapy

Indexed keywords

AR 00454200; AR 00459339; CD135 ANTIGEN; PROTEIN BAD; PROTEIN KINASE B; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; SORAFENIB; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN HL 60; CELL STRAIN MOLM 14; CELL STRAIN MV4 11; CELL STRAIN SEMK2; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTERNAL TANDEM DUPLICATION; LEUKEMOGENESIS; MOLECULARLY TARGETED THERAPY; MONONUCLEAR CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; COLONY-FORMING UNITS ASSAY; DRUG THERAPY, COMBINATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID, ACUTE; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION; TANDEM REPEAT SEQUENCES; TUMOR CELLS, CULTURED;

EID: 84855206895     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.011     Document Type: Article

References (54)

1. Frohling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100:4372-4380.
2. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
3. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
4. Rombouts W.J., Blokland I., Lowenberg B., Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000, 14:675-683.
5. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
6. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
7. Dohner K., Schlenk R.F., Habdank M., Scholl C., Rucker F.G., Corbacioglu A., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106:3740-3746.
8. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
9. Pratz K.W., Cortes J., Roboz G.J., Rao N., Arowojolu O., Stine A., et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009, 113:3938-3946.
10. Smith B.D., Levis M., Beran M., Giles F., Kantarjian H., Berg K., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-3676.
11. Stone R.M., Fischer T., Paquette R., Schiller G., Schiffer C.A., Ehninger G., et al. A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. ASH annual meeting abstracts 2009, 114. Abstract 634.
12. Zarrinkar P.P., Gunawardane R.N., Cramer M.D., Gardner M.F., Brigham D., Belli B., et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114:2984-2992.
13. Zhang W., Konopleva M., Shi Y.X., McQueen T., Harris D., Ling X., et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Journal of the National Cancer Institute 2008, 100:184-198.
14. Cuypers H.T., Selten G., Quint W., Zijlstra M., Maandag E.R., Boelens W., et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984, 37:141-150.
15. Amson R., Sigaux F., Przedborski S., Flandrin G., Givol D., Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989, 86:8857-8861.
16. Mizuki M., Schwable J., Steur C., Choudhary C., Agrawal S., Sargin B., et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003, 101:3164-3173.
17. Cohen A.M., Grinblat B., Bessler H., Kristt D., Kremer A., Schwartz A., et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2004, 45:951-955.
18. Kim K.T., Baird K., Ahn J.Y., Meltzer P., Lilly M., Levis M., et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005, 105:1759-1767.
19. Cibull T.L., Jones T.D., Li L., Eble J.N., Ann Baldridge L., Malott S.R., et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 2006, 59:285-288.
20. Peltola K., Hollmen M., Maula S.M., Rainio E., Ristamaki R., Luukkaa M., et al. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 2009, 11:629-636.
21. Lilly M., Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res 1997, 57:5348-5355.
22. Lilly M., Sandholm J., Cooper J.J., Koskinen P.J., Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999, 18:4022-4031.
23. Miura O., Miura Y., Nakamura N., Quelle F.W., Witthuhn B.A., Ihle J.N., et al. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 1994, 84:4135-4141.
24. Kim K.T., Levis M., Small D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol 2006, 134:500-509.
25. Agrawal S., Koschmieder S., Baumer N., Reddy N.G., Berdel W.E., Muller-Tidow C., et al. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. Leukemia 2008, 22:78-86.
26. Adam M., Pogacic V., Bendit M., Chappuis R., Nawijn M.C., Duyster J., et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res 2006, 66:3828-3835.
27. Levis M., Tse K.F., Smith B.D., Garrett E., Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001, 98:885-887.
28. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
29. Levis M., Allebach J., Tse K.F., Zheng R., Baldwin B.R., Smith B.D., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99:3885-3891.
30. Eswaran J., Patnaik D., Filippakopoulos P., Wang F., Stein R.L., Murray J.W., et al. Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci USA 2009, 106:20198-20203.
31. Yan B., Zemskova M., Holder S., Chin V., Kraft A., Koskinen P.J., et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003, 278:45358-45367.
32. Knapper S., Mills K.I., Gilkes A.F., Austin S.J., Walsh V., Burnett A.K. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 2006, 108:3494-3503.
33. Shiotsu Y., Kiyoi H., Ishikawa Y., Tanizaki R., Shimizu M., Umehara H., et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009, 114:1607-1617.
34. Scheijen B., Ngo H.T., Kang H., Griffin J.D. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004, 23:3338-3349.
35. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005, 65:9643-9650.
36. Choudhary C., Olsen J.V., Brandts C., Cox J., Reddy P.N., Bohmer F.D., et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009, 36:326-339.
37. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003, 9:5465-5476.
38. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105:54-60.
39. DeAngelo D.J., Stone R.M., Heaney M.L., Nimer S.D., Paquette R.L., Klisovic R.B., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108:3674-3681.
40. Quintas-Cardama A., Kantarjian H., Andreef M., Faderl S., Wright J.J., Zhang W., et al. Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML). J Clin Oncol 2007, 25:7018.
41. Mikkers H., Nawijn M., Allen J., Brouwers C., Verhoeven E., Jonkers J., et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004, 24:6104-6115.
42. Pogacic V., Bullock A.N., Fedorov O., Filippakopoulos P., Gasser C., Biondi A., et al. Structural analysis identifies imidazo1,2-bpyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007, 67:6916-6924.
43. Lin Y.W., Beharry Z.M., Hill E.G., Song J.H., Wang W., Xia Z., et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010, 115:824-833.
44. Levis M., Ravandi F., Wang E.S., Baer M.R., Perl A., Coutre S., et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, (January). Epub ahead of print.
45. Serve H., Wagner R., Sauerland C., Brunnberg U., Krug U., Schaich M., et al. Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial. Blood 2010, 116. Abstract 333.
46. Choudhary C., Brandts C., Schwable J., Tickenbrock L., Sargin B., Ueker A., et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007, 110:370-374.
47. Ravandi F., Cortes J.E., Jones D., Faderl S., Garcia-Manero G., Konopleva M.Y., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28:1856-1862.
48. Heidel F., Solem F.K., Breitenbuecher F., Lipka D.B., Kasper S., Thiede M.H., et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006, 107:293-300.
49. von Bubnoff N., Engh R.A., Aberg E., Sanger J., Peschel C., Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009, 69:3032-3041.
50. Weisberg E., Barrett R., Liu Q., Stone R., Gray N., Griffin J.D. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009, 12:81-89.
51. Hochhaus A., Kreil S., Corbin A.S., La Rosee P., Muller M.C., Lahaye T., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
52. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
53. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1018-1029.
54. Pratz K.W., Sato T., Murphy K.M., Stine A., Rajkhowa T., Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010, 115:1425-1432.